Merck announced positive results from the Phase 3 KEYNOTE-966 trial. In the final analysis of this trial, KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) demonstrated a statistically significant and clinically meaningful improvement in overall survival versus chemotherapy alone for the first-line treatment of patients with advanced or unresectable biliary tract cancer. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck picks Perceiv AI for inaugural Digital Sciences Studio cohort
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover
- Merck completes tender offer to acquire Imago BioSciences
- Merck, Pfizer rebuff China’s efforts to cut Covid drug prices, Bloomberg says